8-KMaterial AgreementsFinancial EventsExhibits & Filings

AbbVie Inc. 8-K Report, Material Agreement (Sep 29, 2015)

Filed September 29, 2015For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K on September 29, 2015, to report the establishment of two new credit facilities: a $2 billion three-year term loan credit agreement and a $2 billion 364-day term loan credit agreement, both effective September 25, 2015. These facilities were entered into with Bank of America, N.A. as the administrative agent. The primary purpose of these new credit lines is to address upcoming debt maturities, providing AbbVie with financial flexibility and ensuring continued access to capital. The company has secured a total of $4 billion in new credit, demonstrating its ability to access significant financing. The terms of the loans allow for borrowings at either a base rate or a Eurocurrency rate, with applicable margins varying based on AbbVie's public debt rating, indicating that favorable credit conditions can lead to lower borrowing costs. The agreements include standard covenants and events of default, typical for corporate credit facilities.

Key Highlights

  • 1AbbVie established a $2 billion three-year term loan credit facility.
  • 2AbbVie established a $2 billion 364-day term loan credit facility.
  • 3Total new credit secured amounts to $4 billion.
  • 4The proceeds are intended to address upcoming debt maturities.
  • 5Both facilities were effective as of September 25, 2015.
  • 6Bank of America, N.A. is the administrative agent for both facilities.
  • 7Borrowing interest rates are tied to AbbVie's public debt rating.

Frequently Asked Questions

The primary purpose of both the three-year and 364-day credit agreements is to provide AbbVie with access to funds to address upcoming debt maturities, ensuring the company can meet its financial obligations.

AbbVie has secured a total of $4 billion in new borrowing capacity through these two credit agreements: $2 billion under the three-year facility and $2 billion under the 364-day facility.

AbbVie has the option to borrow under either a Base Rate, which is the prime rate plus an applicable margin, or a Eurocurrency Rate, which is based on LIBOR plus an applicable margin. The specific margins are dependent on AbbVie's public debt rating at the time of borrowing.

Yes, the credit agreements contain customary affirmative covenants, negative covenants, including a financial covenant, and events of default, which are standard provisions in such financing arrangements.